EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study

Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2023.1332232 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Chaojing Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon alpha-2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Among the advantaged population with clinical cure of chronic hepatitis B, chronic inactive hepatitis B virus carriers (IHCs) and nucleoside analog-experienced patients have similar serological manifestations. This study established non-interferon-treated groups as controls to compare the efficacy of pegylated interferon α-2b (Peg-IFNα-2b) in achieving clinical cure between IHCs and nucleoside analog (NA)-experienced patients.

Method

A total of 270 patients were enrolled in this observational study. The IHC cohort comprised 55 patients who received Peg-IFNα-2b (Peg-IFN group), and the other 70 patients did not receive any antiviral treatment (untreated group). Patients treated with NAs were divided into two groups: one group (70 patients) receiving NA add-on Peg-IFNα-2b therapy regimen (NA add-on Peg-IFN group) and another group (75 patients) receiving continuous NA monotherapy (NA group). The primary endpoints were hepatitis B surface antigen (HBsAg) clearance and HBsAg seroconversion at 48 weeks and 72 weeks.

Results

At 48 weeks, 65.5% (36/55) and 52.9% (37/70) patients achieved HBsAg clearance in the Peg-IFN group and NA add-on Peg-IFN group, respectively (p = 0.156). HBsAg seroconversion was achieved in 47.3% (26/55) of the Peg-IFN group and 34.3% (24/70) of the NA add-on Peg-IFN group (p = 0.141). At the follow-up of 72 weeks, 36 patients in the Peg-IFN group achieved HBsAg loss (65.5%, 36/55), and 33 patients in the NA add-on Peg-IFN group achieved HBsAg clearance (47.1%, 33/70), which were significantly higher than in the Peg-IFN group (p = 0.041). The HBsAg seroconversion rates in the Peg-IFN group and NA add-on Peg-IFN group at 72 weeks were 45.5% (25/55) and 32.9% (23/70), respectively (p = 0.151). No patient achieved HBsAg clearance or seroconversion in the NA group and untreated group. Furthermore, the receiver operating characteristic curve showed baseline HBsAg< 72 IU/mL, and the decline of HBsAg of more than 80% and 98% from baseline to 12 and 24 weeks provided good predictions for HBsAg clearance. Meanwhile, 77% of patients with baseline HBsAg< 100 IU/mL achieved a clinical cure at 48 weeks.

Conclusion

Peg-IFNα-2b results in a high rate of HBsAg clearance and seroconversion in both IHCs and NA-experienced patients, especially for those patients who have HBsAg below 100 IU/mL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicInterferon alpha-2HumansAntiviral AgentsHepatitis B Surface AntigensRetrospective StudiesNucleosidesInterferon-alphaPolyethylene GlycolsRecombinant ProteinsTreatment OutcomeHepatitis B virusDNA, Viral

Stichwörter der Autor:innen

HBsAg clearanceHBsAg seroconversionchronic inactive hepatitis B virus carriersclinical curenucleoside analog-experienced patientspegylated interferon α-2b

Substanzen

peginterferon alfa-2bAntiviral AgentsHepatitis B Surface AntigensNucleosidesInterferon-alphaPolyethylene GlycolsRecombinant ProteinsDNA, ViralInterferon alpha-2

Autor:innen und Institutionen

  • Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chon…

Zitieren

APA

Wen, C., Wang, Y., Tian, H., Lei, Y., Wang, Z., Cai, D., Zhou, Z., & Shi, X. (2024). Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1332232

Vancouver

Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, et al. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2023.1332232

BibTeX
@article{Wen2024,
  author = {Wen, Chaojing and Wang, Yixuan and Tian, Haoyue and Lei, Yu and Wang, Zhiyi and Cai, Dachuan and Zhou, Zhi and Shi, Xiaofeng},
  title = {Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2023.1332232}
}
Kostenlos starten →